BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35301312)

  • 1. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
    Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
    Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC; Agosto-Peña J
    Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
    Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
    Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
    Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W
    Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
    Patnaik MM; Tefferi A
    Blood Cancer J; 2016 Feb; 6(2):e393. PubMed ID: 26849014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
    J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation.
    Lin I; Wei A; Awamleh Z; Singh M; Ning A; Herrera A; ; Russell BE; Weksberg R; Arboleda VA
    JCI Insight; 2023 May; 8(10):. PubMed ID: 37053013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
    Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
    Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S; Fujino T; Goyama S; Kitamura T
    Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.